JOP20220153A1 - نظائر الإنكرتين واستخداماتها - Google Patents

نظائر الإنكرتين واستخداماتها

Info

Publication number
JOP20220153A1
JOP20220153A1 JOP/2022/0153A JOP20220153A JOP20220153A1 JO P20220153 A1 JOP20220153 A1 JO P20220153A1 JO P20220153 A JOP20220153 A JO P20220153A JO P20220153 A1 JOP20220153 A1 JO P20220153A1
Authority
JO
Jordan
Prior art keywords
incretin analogs
glucagon
receptors
activity
incretin
Prior art date
Application number
JOP/2022/0153A
Other languages
English (en)
Inventor
Milata Mary Abraham
Jorge Alsina-Fernandez
Tamer Coskun
Hongchang Qu
James Lincoln Wallis
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20220153A1 publication Critical patent/JOP20220153A1/ar
Application granted granted Critical
Publication of JOP20220153B1 publication Critical patent/JOP20220153B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Details Of Garments (AREA)

Abstract

يتعلق الاختراع الحالي بتوفير نظائر الإنكرتين التي لها نشاط عند كل مستقبلات البولي ببتيد الأنسوليني المعتمد على الجلوكوز (GIP)، ببتيد-1 شبيه الجلوكاجون (GLP-1) والجلوكاجون (GCG). يكون لنظائر الإنكرتين سمات بنيوية ينجم عنها نشاط متوازن وفترة ممتدة من التأثير عند كل مستقبل من هذه المستقبلات. يتم كذلك توفير طرق لمعالجة أمراض مثل مرض السكري من النوع 2، عسر شحميات الدم، متلازمة أيضية، مرض الكبد الدهني غير الكحولي، التهاب الكبد الدهني غير الكحولي والسمنة.
JOJO/P/2022/0153A 2019-12-18 2022-06-16 نظائر الإنكرتين واستخداماتها JOP20220153B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962949661P 2019-12-18 2019-12-18
PCT/US2020/064512 WO2021126695A1 (en) 2019-12-18 2020-12-11 Incretin analogs and uses thereof

Publications (2)

Publication Number Publication Date
JOP20220153A1 true JOP20220153A1 (ar) 2023-01-30
JOP20220153B1 JOP20220153B1 (ar) 2025-10-01

Family

ID=74181298

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2022/0153A JOP20220153B1 (ar) 2019-12-18 2022-06-16 نظائر الإنكرتين واستخداماتها

Country Status (22)

Country Link
US (1) US12410227B2 (ar)
EP (1) EP4077365A1 (ar)
JP (1) JP7450724B2 (ar)
KR (1) KR102824306B1 (ar)
CN (1) CN114787183B (ar)
AR (1) AR120714A1 (ar)
AU (1) AU2020408139B2 (ar)
BR (1) BR112022009396A2 (ar)
CL (1) CL2022001623A1 (ar)
CO (1) CO2022008264A2 (ar)
CR (1) CR20220279A (ar)
DO (1) DOP2022000122A (ar)
EC (1) ECSP22048612A (ar)
IL (1) IL293754A (ar)
JO (1) JOP20220153B1 (ar)
MX (1) MX2022007666A (ar)
NZ (1) NZ788683A (ar)
PE (1) PE20221518A1 (ar)
PH (1) PH12022551491A1 (ar)
TW (1) TWI795698B (ar)
WO (1) WO2021126695A1 (ar)
ZA (1) ZA202205443B (ar)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US11813312B2 (en) 2020-04-24 2023-11-14 Boehringer Ingelheim International Gmbh Glucagon analogues as long-acting GLP-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
AU2022392980B2 (en) * 2021-11-19 2025-12-18 Jiangsu Deyuan Pharmaceutical Co., Ltd. Stapled peptide and use thereof
PE20252287A1 (es) 2023-01-31 2025-09-18 Lilly Co Eli Agonistas del trirreceptor gip/glp1/gcg y usos de estos
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
WO2024213022A1 (zh) * 2023-04-11 2024-10-17 上海多米瑞生物技术有限公司 肠促胰素类似物及其制备方法和应用
CN120349393A (zh) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 一种三激动剂化合物
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2528618A4 (en) * 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
US8507428B2 (en) * 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
WO2015095684A1 (en) * 2013-12-20 2015-06-25 Indiana University Research And Technology Corporation Lipidated incretin receptor ligand human immunoglobulin fc-region fusion polypeptides
JO3575B1 (ar) * 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2017116204A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체
AR107890A1 (es) 2016-03-10 2018-06-28 Medimmune Ltd Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
TWI912614B (zh) 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途

Also Published As

Publication number Publication date
PH12022551491A1 (en) 2023-11-20
TW202138385A (zh) 2021-10-16
CL2022001623A1 (es) 2023-01-20
CR20220279A (es) 2022-07-03
US12410227B2 (en) 2025-09-09
JP7450724B2 (ja) 2024-03-15
CN114787183A (zh) 2022-07-22
JP2023506952A (ja) 2023-02-20
MX2022007666A (es) 2022-07-19
ZA202205443B (en) 2025-03-26
WO2021126695A1 (en) 2021-06-24
CO2022008264A2 (es) 2022-07-08
PE20221518A1 (es) 2022-10-04
TWI795698B (zh) 2023-03-11
BR112022009396A2 (pt) 2022-08-09
AR120714A1 (es) 2022-03-09
AU2020408139B2 (en) 2024-03-28
EP4077365A1 (en) 2022-10-26
NZ788683A (en) 2026-01-30
KR20220100676A (ko) 2022-07-15
AU2020408139A1 (en) 2022-06-09
IL293754A (en) 2022-08-01
DOP2022000122A (es) 2022-07-31
JOP20220153B1 (ar) 2025-10-01
US20230102339A1 (en) 2023-03-30
ECSP22048612A (es) 2022-07-29
CN114787183B (zh) 2024-11-26
CA3162245A1 (en) 2021-06-24
KR102824306B1 (ko) 2025-06-25

Similar Documents

Publication Publication Date Title
JOP20220153A1 (ar) نظائر الإنكرتين واستخداماتها
MX2024010201A (es) Analogos de incretina y sus usos.
MX2025003745A (es) Analogos de incretina y sus usos
ZA202106369B (en) Gip/glp1 co-agonist compounds
MY205796A (en) Gipr-agonist compounds
MX2021005835A (es) Compuestos co-agonistas de gip y glp-1.
MX2022014368A (es) Compuesto de agonista doble para receptores de glp-1 y gip y aplicacion del mismo.
MX382408B (es) Coagonistas de los receptores de glucagón y de glp-1.
ZA202310867B (en) Multi-agonist and use thereof
MX2023011278A (es) Composiciones que contienen analogos de incretina y usos de estas.
EA202092891A1 (ru) Соединения-коагонисты gip/glp1
TH2101000319A (th) สารประกอบอะโกนิสท์ร่วม gip/glp1